VivoSeq
Other

Afib

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

AFib is an early-stage landscape with 0 programs across 2 companies. The most active players are Ipsen, Intercept Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ipsen logo

Ipsen

0 programs

PreclinicalI

Intercept Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed4 · 67%
Unknown status1 · 17%
Terminated1 · 17%

Clinical Trials

Trial Activity

6 trials

A Study to Evaluate the Effect of Food on the Level of Circulating Elafibranor in Healthy Participants After Intake of a Single Tablet
Completed·Ipsen logoIpsen·Phase 1·NCT05564208·34 enrolled
Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
Completed·GGenfit·Phase 1·NCT03765671·30 enrolled
Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients
Completed·GGenfit·Phase 1·NCT03844555·23 enrolled
Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants
Completed·Ipsen logoIpsen·Phase 1·NCT05543369·48 enrolled
To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate
Terminated·IIntercept Pharmaceuticals·Phase 3·NCT06488911·63 enrolled
The Effect of Bezafibrate on Cholestatic Itch
Unknown status·—·Phase 3·NCT02701166·84 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)